<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">0376331</journal-id>
<journal-id journal-id-type="pubmed-jr-id">5212</journal-id>
<journal-id journal-id-type="nlm-ta">J Psychiatr Res</journal-id>
<journal-id journal-id-type="iso-abbrev">J Psychiatr Res</journal-id>
<journal-title-group>
<journal-title>Journal of psychiatric research</journal-title>
</journal-title-group>
<issn pub-type="ppub">0022-3956</issn>
<issn pub-type="epub">1879-1379</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27038550</article-id>
<article-id pub-id-type="pmc">6100771</article-id>
<article-id pub-id-type="doi">10.1016/j.jpsychires.2016.03.001</article-id>
<article-id pub-id-type="manuscript">NIHMS774359</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>ESTABLISHING MODERATORS and BIOSIGNATURES OF ANTIDEPRESSANT RESPONSE IN CLINICAL CARE (EMBARC): Rationale and Design</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Trivedi</surname>
<given-names>Madhukar H.</given-names>
</name>
<xref ref-type="author-notes" rid="FN1">*</xref>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>McGrath</surname>
<given-names>Patrick J.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fava</surname>
<given-names>Maurizio</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Parsey</surname>
<given-names>Ramin V.</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kurian</surname>
<given-names>Benji T.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Phillips</surname>
<given-names>Mary L.</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Oquendo</surname>
<given-names>Maria A.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bruder</surname>
<given-names>Gerard</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pizzagalli</surname>
<given-names>Diego</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Toups</surname>
<given-names>Marisa</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cooper</surname>
<given-names>Crystal</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Adams</surname>
<given-names>Phil</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Weyandt</surname>
<given-names>Sarah</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Morris</surname>
<given-names>David W.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Grannemann</surname>
<given-names>Bruce D.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ogden</surname>
<given-names>R. Todd</given-names>
</name>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Buckner</surname>
<given-names>Randy</given-names>
</name>
<xref ref-type="aff" rid="A8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>McInnis</surname>
<given-names>Melvin</given-names>
</name>
<xref ref-type="aff" rid="A9">9</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kraemer</surname>
<given-names>Helena C.</given-names>
</name>
<xref ref-type="aff" rid="A10">10</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Petkova</surname>
<given-names>Eva</given-names>
</name>
<xref ref-type="aff" rid="A11">11</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Carmody</surname>
<given-names>Thomas J.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Weissman.</surname>
<given-names>Myrna M.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>University of Texas, Southwestern Medical Center, Dallas, TX</aff>
<aff id="A2">
<label>2</label>New York State Psychiatric Institute &amp; Department of Psychiatry, College of Physicians and Surgeons of Columbia University, New York, NY</aff>
<aff id="A3">
<label>3</label>Massachusetts General Hospital, Boston, MA</aff>
<aff id="A4">
<label>4</label>Stony Brook University, Stony Brook, NY</aff>
<aff id="A5">
<label>5</label>University of Pittsburgh, Pittsburgh, PA</aff>
<aff id="A6">
<label>6</label>Harvard Medical School â€“ McLean Hospital, Boston, MA</aff>
<aff id="A7">
<label>7</label>Columbia University, New York, NY</aff>
<aff id="A8">
<label>8</label>Harvard University, Cambridge, MA</aff>
<aff id="A9">
<label>9</label>University of Michigan, Ann Arbor, MI</aff>
<aff id="A10">
<label>10</label>Stanford University, Stanford, CA</aff>
<aff id="A11">
<label>11</label>New York University, New York, NY</aff>
<author-notes>
<corresp id="FN1"><label>*</label>Corresponding Author: Madhukar H. Trivedi, M.D., Professor of Psychiatry Betty Jo Hay Distinguished Chair in Mental Health, Director, Center for Depression Research and Clinical Care, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd. Dallas, TX 75390-9119, Phone: 214-648-0188, Fax: 214-648-0167, <email>madhukar.trivedi@utsouthwestern.edu</email></corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>27</day>
<month>11</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>15</day>
<month>3</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<month>7</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>20</day>
<month>8</month>
<year>2018</year>
</pub-date>
<volume>78</volume>
<fpage>11</fpage>
<lpage>23</lpage>
<!--elocation-id from pubmed: 10.1016/j.jpsychires.2016.03.001-->
<abstract>
<p id="P1">Remission rates for Major Depressive Disorder (MDD) are low and unpredictable for any given antidepressant. No biological or clinical marker has demonstrated sufficient ability to match individuals to efficacious treatment. Biosignatures developed from the systematic exploration of multiple biological markers, which optimize treatment selection for individuals (moderators) and provide early indication of ultimate treatment response (mediators) are needed. The rationale and design of a multi-site, placebo-controlled randomized clinical trial of sertraline examining moderators and mediators of treatment response is described. The target sample is 400 participants with early onset (&lt;30 years) recurrent MDD. Non-responders to an 8-week trial are switched double blind to either bupropion (for sertraline non-responders) or sertraline (for placebo non-responders) for an additional 8 weeks. Clinical moderators include anxious depression, early trauma, gender, melancholic and atypical depression, anger attacks, Axis II disorder, hypersomnia/fatigue, and chronicity of depression. Biological moderator and mediators include cerebral cortical thickness, task-based fMRI (reward and emotion conflict), resting connectivity, diffusion tensor imaging (DTI), arterial spin labeling (ASL), electroencephalograpy (EEG), cortical evoked potentials, and behavioral/cognitive tasks evaluated at baseline and week 1, except DTI, assessed only at baseline. The study is designed to standardize assessment of biomarkers across multiple sites as well as institute replicable quality control methods, and to use advanced data analytic methods to integrate these markers. A Differential Depression Treatment Response Index (DTRI) will be developed. The data, including biological samples (DNA, RNA, and plasma collected before and during treatment), will become available in a public scientific repository.</p>
</abstract>
<kwd-group>
<kwd>Biosignatures</kwd>
<kwd>antidepressant response</kwd>
<kwd>Moderators</kwd>
<kwd>Mediators</kwd>
<kwd>EMBARC</kwd>
<kwd>sertraline</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>